Long-term SARS-CoV-2-specific immune and inflammatory responses in individuals recovering from COVID-19 with and without post-acute symptoms

Cell Reports

卷:36

Nikita S. Iyer¹  Jeffrey N. Martin¹  Amelia N. Deitchman²  Isabel Rodriguez-Barraquer²  Steven G. Deeks³  Bryan Greenhouse³  Cassandra Thanh⁴  Sadie E. Munter⁴  Joanna Donatelli⁴  Saki Takahashi⁴  Christopher C. Nixon⁴  Yanel Hernandez⁵  Rachel L. Rutishauser⁵  Matthew A. Spinelli⁵  Keirstinne Turcios⁵  Emily A. Fehrman⁵  Jill Hakim⁵  Monica Gandhi⁵  Rebecca Hoh⁵  Leonel Torres⁵  Michael J. Peluso⁵  Viva Tai⁵  Timothy J. Henrich⁵  Owen Janson⁵  J. Daniel Kelly⁵  Lan Trinh⁵  Terri Wrin⁶  Christos J. Petropoulos⁶  Francesca T. Aweeka⁶ 

[1] Division of Experimental Medicine, University of California, San Francisco, San Francisco, CA, USA;

[2] Department of Clinical Pharmacy, University of California, San Francisco, CA, USA;

[3] Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA, USA;

[4] Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, San Francisco, CA, USA;

[5] Monogram Biosciences, Inc., South San Francisco, CA, USA;

关键词: SARS-CoV-2;    COVID-19;    T cell;    immunity;    post-acute sequelae of SARS-CoV-2 infection;    PASC;   

DOI  :  

来源: DOAJ

【 摘 要 】

Summary: We describe severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cell responses, soluble markers of inflammation, and antibody levels and neutralization capacity longitudinally in 70 individuals with PCR-confirmed SARS-CoV-2 infection. Participants represent a spectrum of illness and recovery, including some with persistent viral shedding in saliva and many experiencing post-acute sequelae of SARS-CoV-2 infection (PASC). T cell responses remain stable for up to 9 months. Whereas the magnitude of early CD4+ T cell immune responses correlates with severity of initial infection, pre-existing lung disease is independently associated with higher long-term SARS-CoV-2-specific CD8+ T cell responses. Among participants with PASC 4 months following coronavirus disease 2019 (COVID-19) symptom onset, we observe a lower frequency of CD8+ T cells expressing CD107a, a marker of degranulation, in response to Nucleocapsid (N) peptide pool stimulation, and a more rapid decline in the frequency of N-specific interferon-γ-producing CD8+ T cells. Neutralizing antibody levels strongly correlate with SARS-CoV-2-specific CD4+ T cell responses.

【 授权许可】

Unknown